{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.67","upperLimit":"11.6","value":"5.772"},{"groupId":"OG002","lowerLimit":"3.68","upperLimit":"7.90","value":"5.858"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 1 week 1 day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.10","upperLimit":"11.3","value":"5.448"},{"comment":"Here, \"NA\" indicates that data could not be evaluated due to smaller number of participants.","groupId":"OG001","lowerLimit":"6.80","upperLimit":"6.80","value":"NA"},{"groupId":"OG002","lowerLimit":"4.11","upperLimit":"9.71","value":"5.250"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 1 week 2 day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.15","upperLimit":"10.5","value":"5.435"},{"comment":"Here, \"NA\" indicates that data could not be evaluated due to smaller number of participants.","groupId":"OG001","lowerLimit":"5.09","upperLimit":"5.09","value":"NA"},{"groupId":"OG002","lowerLimit":"3.93","upperLimit":"23.5","value":"5.499"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"title":"Cycle 1 week 3 day 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.50","upperLimit":"16.0","value":"6.669"},{"groupId":"OG002","lowerLimit":"3.56","upperLimit":"14.7","value":"4.323"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"title":"Cycle 2 day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"description":"The plasma PK of AZD4573 when administered in participants was assessed.","dispersionType":"Full Range","groups":[{"description":"Participants with non-NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG000","title":"Cohort 1 Non-NK PTCL"},{"description":"Participants with NK PTCL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG001","title":"Cohort 2 NK PTCL"},{"description":"Participants with cHL received 12 mg dose of AZD4573 once weekly until disease progression.","id":"OG002","title":"Cohort 3 cHL"}],"paramType":"MEDIAN","populationDescription":"PK set included all participants who received any amount of study intervention with at least 1 reportable concentration. Here, 'n\" (number analyzed in each row) signifies the participants with available data that were analyzed for each timepoint of this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 (Cycle length is 35 days), Day 1 of Weeks 1-3 and Cycle 2 (Cycle length is 21 Days), Day 1.","title":"Half-life (t1/2) of AZD4573","type":"SECONDARY","unitOfMeasure":"Hour"}